Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
ANTI-T CELL ANTIGEN BINDING MOLECULES FOR USE IN COMBINATION WITH ANGIOGENESIS INHIBITORS
Document Type and Number:
Japanese Patent JP2023078311
Kind Code:
A
Abstract:
To provide compositions and methods for the prevention, alleviation, or treatment of cytokine release or side effects due to cytokine release associated with administration of an anti-T Cell antigen-binding molecule to a subject.SOLUTION: Provided is a pharmaceutical composition containing an anti-T cell antigen-binding molecule, the pharmaceutical composition being characterized in that it is used in combination with a vascular epithelial cell growth factor (VEGF) inhibitor, the anti-T cell antigen-binding molecule comprising: (1) a domain containing an antibody variable region having CD3 binding activity; and (2) a domain containing an antibody variable region having glypican 3-binding activity, and the VEGF inhibitor being selected from the group consisting of bevacizumab, ramucirumab, and aflibercept.SELECTED DRAWING: Figure 2-A

Inventors:
TANAKA TAKAYOSHI
SANO YUJI
KAWAI YUMIKO
Application Number:
JP2023043678A
Publication Date:
June 06, 2023
Filing Date:
March 20, 2023
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
CHUGAI PHARMACEUTICAL CO LTD
International Classes:
A61K39/395; A61K31/56; A61K31/573; A61P35/00; A61P37/02; A61P43/00; C07K14/705; C07K16/00; C07K16/24; C07K16/28; C07K19/00; C12N15/12; C12N15/13; C12N15/62
Attorney, Agent or Firm:
Masao Haruna
Hatsushi Shimizu
Hirotaka Yamaguchi
Shun Jinbe
Ryuichi Inoue
Toshimitsu Sato
Kousuke Umemura
Koichi Niimi
Tomohiko Kobayashi
Hideki Kodera
Masato Ozeki
Maki Shioda
Kazuya Kawamoto